MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 527758 | Name: 7-OH-DPAT Hydrobromide
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

7-OH-DPAT Hydrobromide is a potent and selective Dopamine D3 receptor agonist.

Chemical Structure

7-OH-DPAT Hydrobromide
7-OH-DPAT Hydrobromide
CAS#76135-30-3

Theoretical Analysis

MedKoo Cat#: 527758

Name: 7-OH-DPAT Hydrobromide

CAS#: 76135-30-3

Chemical Formula: C16H26BrNO

Exact Mass: 327.1198

Molecular Weight: 328.29

Elemental Analysis: C, 58.54; H, 7.98; Br, 24.34; N, 4.27; O, 4.87

Price and Availability

Size Price Availability Quantity
10mg USD 350.00 2 Weeks
50mg USD 750.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
7-OH-DPAT Hydrobromide
IUPAC/Chemical Name
7-Hydroxy-N,N-dipropyl-2-aminotetralin hydrobromide
InChi Key
ODNDMTWHRYECKX-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H25NO.BrH/c1-3-9-17(10-4-2)15-7-5-13-6-8-16(18)12-14(13)11-15;/h6,8,12,15,18H,3-5,7,9-11H2,1-2H3;1H
SMILES Code
CCCN(CCC)C1CC2=C(C=CC(O)=C2)CC1.[H]Br
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 328.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Eguibar JR, Cortes Mdel C, Lara-Lozano M, Mendiola DM. Dopaminergic D2-like agonists produce yawning in the myelin mutant taiep and Sprague-Dawley rats. Pharmacol Biochem Behav. 2012 Jul;102(1):118-23. doi: 10.1016/j.pbb.2012.03.020. Epub 2012 Mar 31. PubMed PMID: 22497991. 2: Yoshizawa K, Narita M, Mori T, Miyatake M, Isotani K, Tomiyasu S, Tsukiyama Y, Suzuki T. Role of dopamine D2 and D3 receptors in mediating the U-50,488H discriminative cue: comparison with methamphetamine and cocaine. Addict Biol. 2012 Nov;17(6):949-55. doi: 10.1111/j.1369-1600.2010.00257.x. Epub 2010 Nov 4. PubMed PMID: 21054688. 3: Maina FK, Mathews TA. A functional fast scan cyclic voltammetry assay to characterize dopamine D2 and D3 autoreceptors in the mouse striatum. ACS Chem Neurosci. 2010 Mar 12;1(6):450-462. PubMed PMID: 20567609; PubMed Central PMCID: PMC2887711. 4: Everett PB, Senogles SE. D3 dopamine receptor signals to activation of phospholipase D through a complex with Rho. J Neurochem. 2010 Feb;112(4):963-71. doi: 10.1111/j.1471-4159.2009.06508.x. Epub 2009 Dec 18. PubMed PMID: 20021566. 5: Kitrey ND, Clément P, Bernabé J, Alexandre L, Giuliano F. Microinjection of the preferential dopamine receptor D3 agonist 7-hydroxy-N,N-di-n-propylaminotetralin hydrobromide into the hypothalamic medial preoptic area induced ejaculation in anesthetized rats. Neuroscience. 2007 Nov 9;149(3):636-41. Epub 2007 Jul 20. PubMed PMID: 17916409. 6: Ito S, Mori T, Sawaguchi T. Differential effects of micro-opioid, delta-opioid and kappa-opioid receptor agonists on dopamine receptor agonist-induced climbing behavior in mice. Behav Pharmacol. 2006 Dec;17(8):691-701. PubMed PMID: 17110795. 7: Collins GT, Witkin JM, Newman AH, Svensson KA, Grundt P, Cao J, Woods JH. Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior. J Pharmacol Exp Ther. 2005 Jul;314(1):310-9. Epub 2005 Apr 15. PubMed PMID: 15833897; PubMed Central PMCID: PMC1201434. 8: Rogóz Z, Skuza G, Kłlodzińska A. Anxiolytic- and antidepressant-like effects of 7-OH-DPAT, preferential dopamine D3 receptor agonist, in rats. Pol J Pharmacol. 2004 Sep-Oct;56(5):519-26. PubMed PMID: 15591639. 9: Cook CD, Beardsley PM. Modulation of the discriminative stimulus effects of mu opioid agonists in rats: II. Effects of dopamine D2/3 agonists. Behav Pharmacol. 2004 Feb;15(1):75-83. PubMed PMID: 15075629. 10: Rogóz Z, Skuza G, Kłodzińska A. Anxiolytic-like effects of preferential dopamine D3 receptor agonists in an animal model. Pol J Pharmacol. 2003 May-Jun;55(3):449-54. PubMed PMID: 14506325. 11: Skuza G, Rogóz Z. A potential antidepressant activity of SA4503, a selective sigma 1 receptor agonist. Behav Pharmacol. 2002 Nov;13(7):537-43. PubMed PMID: 12409992. 12: Ottani A, Ferrari F, Giuliani D. Neuroleptic-like profile of the cannabinoid agonist, HU 210, on rodent behavioural models. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Jan;26(1):91-6. PubMed PMID: 11853125. 13: Levens N, Green TA, Akins CK, Bardo MT. Dopamine D(2)-like receptor binding in the brain of male Japanese quail (Coturnix japonica). Neurosci Lett. 2000 Dec 22;296(2-3):77-80. PubMed PMID: 11108985. 14: Dastur FN, McGregor IS, Brown RE. Dopaminergic modulation of rat pup ultrasonic vocalizations. Eur J Pharmacol. 1999 Oct 8;382(2):53-67. PubMed PMID: 10528139. 15: Geter-Douglass B, Katz JL, Alling K, Acri JB, Witkin JM. Characterization of unconditioned behavioral effects of dopamine D3/D2 receptor agonists. J Pharmacol Exp Ther. 1997 Oct;283(1):7-15. PubMed PMID: 9336302. 16: Mallet PE, Beninger RJ. 7-OH-DPAT produces place conditioning in rats. Eur J Pharmacol. 1994 Aug 22;261(3):R5-6. PubMed PMID: 7813542.